Replies to post #52072 on Biotech Values

[DewDiligence]

>Maybe I'm more suspicious with Lilly after the Zyprexa case but those points are disturbing.<

The dropout numbers are indeed odd. I wouldn’t be suspicious on account of LLY’s off-label marketing of Zyprexa. However, I might be suspicious inasmuch as LLY absolutely, positively needs a blockbuster encore to Zyprexa or the company’s financials will be in deep doo-doo. Regards, Dew